- "Based on the ratio of NRx/TRx, refill rates appear to be low," Needham's Alan Carr says, referring to Arena's (NASDAQ:ARNA) Belviq.
- The shares rallied sharply Tuesday, after marketing partner Eisai (OTCPK:ESALF) said it will double its sales force for the weight-loss drug.
- Nevertheless, Carr says "Belviq patient awareness [is] low." The analyst also calls single-agent efficacy "modest."
- Hold rating reiterated.
- ARNA +1.3% premarket.